JP2008538178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538178A5 JP2008538178A5 JP2008503516A JP2008503516A JP2008538178A5 JP 2008538178 A5 JP2008538178 A5 JP 2008538178A5 JP 2008503516 A JP2008503516 A JP 2008503516A JP 2008503516 A JP2008503516 A JP 2008503516A JP 2008538178 A5 JP2008538178 A5 JP 2008538178A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- agrin
- protein
- variant
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 17
- 101150079978 AGRN gene Proteins 0.000 claims 15
- 108700019743 Agrin Proteins 0.000 claims 15
- 102100040026 Agrin Human genes 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 238000003776 cleavage reaction Methods 0.000 claims 9
- 230000007017 scission Effects 0.000 claims 7
- 239000003550 marker Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 101001023733 Homo sapiens Neurotrypsin Proteins 0.000 claims 4
- 102100035484 Neurotrypsin Human genes 0.000 claims 4
- 108091005804 Peptidases Proteins 0.000 claims 4
- 239000004365 Protease Substances 0.000 claims 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- 108010037733 neurotrypsin Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 108091035707 Consensus sequence Proteins 0.000 claims 2
- 239000012062 aqueous buffer Substances 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 108010000845 C-terminal agrin fragment Proteins 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 229940100584 Neurotrypsin inhibitor Drugs 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000946 synaptic effect Effects 0.000 claims 1
- 0 *c(cc1*)cc(C=Nc(cc2)ccc2S(NC(N)=N)(=O)=O)c1O Chemical compound *c(cc1*)cc(C=Nc(cc2)ccc2S(NC(N)=N)(=O)=O)c1O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05102481 | 2005-03-30 | ||
| EP05102481.8 | 2005-03-30 | ||
| PCT/EP2006/061152 WO2006103261A2 (en) | 2005-03-30 | 2006-03-29 | Inhibitors of neurotrypsin and determination thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008538178A JP2008538178A (ja) | 2008-10-16 |
| JP2008538178A5 true JP2008538178A5 (https=) | 2009-05-14 |
| JP4920675B2 JP4920675B2 (ja) | 2012-04-18 |
Family
ID=34939082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503516A Expired - Fee Related JP4920675B2 (ja) | 2005-03-30 | 2006-03-29 | ニューロトリプシン阻害剤とその判定 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7897364B2 (https=) |
| EP (1) | EP1868989A2 (https=) |
| JP (1) | JP4920675B2 (https=) |
| KR (1) | KR20070116932A (https=) |
| CN (1) | CN101193858B (https=) |
| AU (1) | AU2006228150B2 (https=) |
| BR (1) | BRPI0609654A2 (https=) |
| CA (1) | CA2600791A1 (https=) |
| IL (1) | IL186120A (https=) |
| MX (1) | MX2007011961A (https=) |
| NO (1) | NO20075461L (https=) |
| NZ (1) | NZ562796A (https=) |
| RU (1) | RU2424228C2 (https=) |
| WO (1) | WO2006103261A2 (https=) |
| ZA (1) | ZA200707359B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008074813A2 (en) * | 2006-12-21 | 2008-06-26 | Neurotune Ag | Optiogenin for the treatment of neural diseases |
| PL1990420T3 (pl) * | 2007-05-10 | 2011-01-31 | Neurotune Ag | Sposób wykrywania aktywności neurotrypsyny in vivo, zastosowanie tego sposobu i zastosowanie C-końcowego fragmentu agryny 22 kDa jako biomarkera w diagnozowaniu i monitorowaniu zaburzeń związanych z neurotrypsyną |
| EP2295068A1 (en) * | 2009-09-04 | 2011-03-16 | Neurotune AG | Modified agrin-fragment capable of restoring muscle strength for use as a medicament |
| EP2635559A2 (en) | 2010-11-01 | 2013-09-11 | Neurotune AG | Neurotrypsin inhibitors |
| WO2012059443A2 (en) | 2010-11-01 | 2012-05-10 | Neurotune Ag | Novel neurotrypsin inhibitors |
| EP2631657A1 (en) * | 2012-02-25 | 2013-08-28 | Neurotune AG | Immunoassay for the detection of the 22kDa C-terminal fragment (CAF) of agrin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH692507A5 (de) * | 1997-04-26 | 2002-07-15 | Peter Prof Dr Sonderegger | Neurotrypsin als aktive Verbindung in einem Medikament. |
| DE19919634C2 (de) * | 1999-04-30 | 2001-06-07 | Aventis Pharma Gmbh | Test zur Bestimmung der Integrität komplexer Phospholipid/Lipid-Strukturen mit Hilfe synthetischer fluoreszenz-markierter Acylglyceride und dessen Anwendung zur Bestimmung der Aktivität von Lipasen |
| DE10247478A1 (de) * | 2002-10-11 | 2004-06-24 | Bioagency Ag | Verfahren zur Bestimmung der enzymatischen Aktivität von Proteinen |
-
2006
- 2006-03-29 WO PCT/EP2006/061152 patent/WO2006103261A2/en not_active Ceased
- 2006-03-29 RU RU2007139754/04A patent/RU2424228C2/ru not_active IP Right Cessation
- 2006-03-29 AU AU2006228150A patent/AU2006228150B2/en not_active Ceased
- 2006-03-29 JP JP2008503516A patent/JP4920675B2/ja not_active Expired - Fee Related
- 2006-03-29 KR KR1020077024937A patent/KR20070116932A/ko not_active Withdrawn
- 2006-03-29 US US11/887,136 patent/US7897364B2/en not_active Expired - Fee Related
- 2006-03-29 CA CA002600791A patent/CA2600791A1/en not_active Abandoned
- 2006-03-29 CN CN2006800101171A patent/CN101193858B/zh not_active Expired - Fee Related
- 2006-03-29 MX MX2007011961A patent/MX2007011961A/es not_active Application Discontinuation
- 2006-03-29 NZ NZ562796A patent/NZ562796A/en not_active IP Right Cessation
- 2006-03-29 BR BRPI0609654-9A patent/BRPI0609654A2/pt not_active IP Right Cessation
- 2006-03-29 EP EP06725408A patent/EP1868989A2/en not_active Withdrawn
-
2007
- 2007-08-29 ZA ZA200707359A patent/ZA200707359B/xx unknown
- 2007-09-20 IL IL186120A patent/IL186120A/en not_active IP Right Cessation
- 2007-10-29 NO NO20075461A patent/NO20075461L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 | |
| Osman et al. | Why all the fury over furin? | |
| JP5008398B2 (ja) | クラスｉ膜融合誘発性エンベロープタンパク質をもつｒｎａウイルスの融合開始領域の機能を阻害することによってウイルス：細胞融合を妨げる方法 | |
| EP1910837B1 (en) | Methods and compositions for diagnosis and treatment of influenza | |
| Sainz Jr et al. | Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein | |
| Petit et al. | Palmitoylation of the cysteine-rich endodomain of the SARS–coronavirus spike glycoprotein is important for spike-mediated cell fusion | |
| Ghosh et al. | Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors | |
| Ghildyal et al. | Nuclear import of the respiratory syncytial virus matrix protein is mediated by importin β1 independent of importin α | |
| Guay et al. | Therapeutic utility and medicinal chemistry of cathepsin C inhibitors | |
| Prusis et al. | Design and evaluation of substrate-based octapeptide and non substrate-based tetrapeptide inhibitors of dengue virus NS2B–NS3 proteases | |
| Ho et al. | Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction | |
| JP2008538178A5 (https=) | ||
| Brady et al. | Rational design and synthesis of selective BACE-1 inhibitors | |
| Liu et al. | Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease | |
| El Najjar et al. | Analysis of cathepsin and furin proteolytic enzymes involved in viral fusion protein activation in cells of the bat reservoir host | |
| Cascio et al. | Structural determinants driving the binding process between PDZ domain of wild type human PALS1 protein and SLiM sequences of SARS-CoV E proteins | |
| Lange et al. | Fragment‐Based Design, Synthesis, and Characterization of Aminoisoindole‐Derived Furin Inhibitors | |
| Shuai et al. | An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo | |
| RU2007139754A (ru) | Ингибиторы нейротрипсина | |
| CN101287988A (zh) | 用于流感诊断和治疗的方法和组合物 | |
| Meanwell et al. | Respiratory syncytial virus–the discovery and optimization of orally bioavailable fusion inhibitors | |
| Liu et al. | Simple nano-luciferase-based assay for the rapid and high-throughput detection of SARS-CoV-2 3C-like protease | |
| Galanopoulos et al. | Molecular analysis of hot-spot regions of ACE2 and TMPRSS2 in SARS-CoV-2 “invulnerable” individuals | |
| JP2008522632A5 (https=) | ||
| US10502741B2 (en) | Means and methods for detecting activated MALT1 |